Sun Pharma Advanced Research Company Limited (SPARC.NS) Bundle
Who's buying Sun Pharma Advanced Research Company Limited and what does the shareholder map tell us about future momentum? Major promoter Shanghvi Finance Private Limited held a commanding 44.18% stake as of 6 Jan 2023 (down from 52.07% pre-warrant conversion), while retail investors collectively own about 18.99% as of 17 Jul 2025, the Sun Pharma Key Employees Benefit Trust holds 3.18%, and institutional interest remains muted with mutual funds at 1.01% and foreign institutional investors at 1.45% (no pledged promoter holdings reported as of 17 Jul 2025); juxtapose that ownership concentration with market realities - SPARC closed at ₹136.84 on 12 Dec 2025 (‑0.34%), a market cap of ₹44.41 billion and a 52‑week band of ₹109.30-241.00, while recent financials show a Q2 FY26 net loss of ₹75.85 crore (down 29.33% YoY) and revenue of ₹7.86 crore (down 38.88%), and balance those headwinds against strategic positives such as oncology/immunology programs - Vodobatinib (SCO‑088) and Vibozilimod (SCD‑044) in Phase‑2 and targeted partnerships - to decide whether SPARC's promoter‑heavy ownership, thin institutional base and current valuation create opportunity or risk; read on to unpack who's steering the ship and why investors are still watching.
Sun Pharma Advanced Research Company Limited (SPARC.NS) - Who Invests in Sun Pharma Advanced Research Company Limited (SPARC.NS) and Why?
Sun Pharma Advanced Research Company Limited (SPARC.NS) exhibits a concentrated promoter ownership with a significant retail presence and limited institutional participation. Investor motivations vary by category - strategic control and long-term value capture for promoters, belief in R&D-driven upside for insiders and retail, and selective exposure for institutions.- Promoter (Shanghvi Finance Private Limited - SFPL): strategic control, long-term value, and linkage to parent-group R&D strategy.
- Individual investors: retail conviction in drug-development milestones, speculation on licensing/partnership outcomes, and dividend/total-return expectations.
- Key Employees Benefit Trust: alignment of management incentives with company performance and confidence in pipeline prospects.
- Mutual funds and Foreign Institutional Investors (FIIs): limited, selective exposure-often driven by risk-reward assessment of late-stage R&D assets and portfolio allocation rules.
- No pledged promoter holdings: reduces perceived financial distress risk and supports governance confidence among investors.
| Investor Category | Holding (%) | Reference Date | Notes |
|---|---|---|---|
| Shanghvi Finance Private Limited (SFPL) | 44.18% | Jan 6, 2023 | Reduced from 52.07% after warrant conversion; remains dominant promoter holder |
| Individual investors (Retail) | 18.99% | Jul 17, 2025 | Diversified retail base driving liquidity and retail sentiment |
| Sun Pharmaceutical Industries Key Employees Benefit Trust | 3.18% | Jul 17, 2025 | Indicates internal confidence and executive alignment |
| Mutual Funds | 1.01% | Jul 17, 2025 | Limited mutual fund allocation-suggests cautious institutional stance |
| Foreign Institutional Investors (FIIs) | 1.45% | Jul 17, 2025 | Modest FII interest-likely selective, event-driven investments |
| Pledged Promoter Holdings | 0.00% | Jul 17, 2025 | No pledged shares reported-signals lower financial leverage risk among promoters |
- Implications for investors: concentrated promoter control can support stable strategic direction but may limit free-float and institutional liquidity; retail presence can amplify volatility around pipeline news.
- Why investors stay or enter: belief in SPARC's drug-development pipeline, potential licensing deals, parent-group synergies, and upside from successful clinical/commercial milestones.
Sun Pharma Advanced Research Company Limited (SPARC.NS) - Institutional Ownership and Major Shareholders of Sun Pharma Advanced Research Company Limited
- Major promoter: Shanghvi Finance Private Limited (SFPL) - stake reduced from 52.07% to 44.18% following conversion of warrants into equity (as of 06-Jan-2023).
- Insider confidence: The Sun Pharmaceutical Industries Key Employees Benefit Trust holds 3.18% (as of 17-Jul-2025).
- Limited institutional participation: Mutual funds hold 1.01% and foreign institutional investors hold 1.45% (as of 17-Jul-2025).
- No pledged promoter holdings reported (as of 17-Jul-2025), indicating absence of promoter-side leverage or immediate financial distress signals.
| Shareholder / Category | Stake (%) | Reference Date | Notes |
|---|---|---|---|
| Shanghvi Finance Private Limited (SFPL) | 44.18 | 06-Jan-2023 | Reduced from 52.07% after warrant conversion |
| The Sun Pharmaceutical Industries Key Employees Benefit Trust | 3.18 | 17-Jul-2025 | Employee trust - signals internal alignment |
| Mutual Funds | 1.01 | 17-Jul-2025 | Low mutual fund ownership |
| Foreign Institutional Investors (FIIs) | 1.45 | 17-Jul-2025 | Limited foreign institutional interest |
| Pledged Promoter Holdings | 0.00 | 17-Jul-2025 | No pledged shares reported |
- Implications for liquidity: High promoter concentration (SFPL + promoter-related holdings) with muted mutual fund/FII stakes can constrain daily free-float and trading turnover.
- Investor perception: Strong promoter control may be viewed as stability by long-term investors but may deter passive/index-linked funds and investors preferring higher institutional oversight.
- Governance signals: No pledged holdings and an employee trust presence point to positive governance/commitment signals, though limited external institutional scrutiny remains.
Sun Pharma Advanced Research Company Limited (SPARC.NS) Key Investors and Their Impact on Sun Pharma Advanced Research Company Limited (SPARC.NS)
Sun Pharma Advanced Research Company Limited (SPARC.NS) exhibits a concentrated ownership profile dominated by promoter holdings with relatively limited institutional participation. Key ownership moves and current stakes influence governance dynamics, liquidity and investor perception.- Shanghvi Finance Private Limited (SFPL) reduced its stake from 52.07% to 44.18% as of January 6, 2023, following conversion of warrants into equity - a material reduction in promoter concentration.
- The Sun Pharmaceutical Industries Key Employees Benefit Trust holds 3.18% as of July 17, 2025, signalling internal confidence and management/aligned insider ownership.
- Mutual funds and foreign institutional investors hold modest stakes of 1.01% and 1.45% respectively as of July 17, 2025, indicating limited institutional demand.
- No pledged promoter holdings reported as of July 17, 2025, which reduces immediate financial distress concerns among major shareholders.
| Investor | Holding (%) | Reference Date | Notes |
|---|---|---|---|
| Shanghvi Finance Private Limited (SFPL) | 44.18% | Jan 6, 2023 | Promoter; stake reduced from 52.07% after warrant conversion |
| The Sun Pharmaceutical Industries Key Employees Benefit Trust | 3.18% | Jul 17, 2025 | Insider/employee trust; indicates internal confidence |
| Mutual Funds | 1.01% | Jul 17, 2025 | Limited domestic institutional ownership |
| Foreign Institutional Investors (FIIs) | 1.45% | Jul 17, 2025 | Low foreign institutional interest |
| Public / Others (implied free float) | 50.18% | Calculated | Residual free float after major holdings |
- Liquidity: High promoter concentration (SFPL 44.18%) combined with small institutional stakes can reduce trade depth and increase bid-ask volatility, particularly around news events.
- Governance & control: Large promoter holding maintains decision-making control; employee trust (3.18%) aligns management incentives with shareholders.
- Institutional appeal: Low mutual fund (1.01%) and FII (1.45%) participation may limit attention from large asset managers and index trackers, affecting demand-side flows.
- Risk signal: Absence of pledged promoter holdings as of Jul 17, 2025 lowers immediate leverage-related risk, though concentrated ownership still concentrates execution risk.
Sun Pharma Advanced Research Company Limited (SPARC.NS) - Market Impact and Investor Sentiment
Sun Pharma Advanced Research Company Limited (SPARC.NS) is trading under clear market pressure as investors weigh recent weak results against long-term pipeline potential. Key market and financial datapoints point to heightened volatility and mixed sentiment.- Stock price: closed at ₹136.84 on December 12, 2025 (down 0.34% day-over-day).
- Market capitalization: ₹44.41 billion.
- 52-week range: ₹109.30 - ₹241.00, indicating large intrayear swings and speculative interest.
| Metric | Value |
|---|---|
| Latest close (12-Dec-2025) | ₹136.84 |
| Market cap | ₹44.41 billion |
| 52-week low / high | ₹109.30 / ₹241.00 |
| Q2 FY26 Net result | Net loss ₹75.85 crore (YoY decline 29.33%) |
| Q2 FY26 Revenue | ₹7.86 crore (down 38.88% YoY; lowest on record) |
| Operating margin | Negative |
| Book value | Negative (reported) |
- Buyer profiles currently active:
- Specialty biotech funds and venture-style investors attracted to oncology/immunology pipeline upside.
- Event-driven and activist investors monitoring asset commercialization or licensing opportunities.
- Short-term traders and momentum funds capitalizing on high intraday/weekly volatility.
- Catalysts that could shift sentiment:
- Positive phase-2 readouts for SCO-088 or SCD-044.
- Licensing deals, out-licensing, or milestone-bearing partnerships.
- Operational turnaround evidence (revenue recovery, margin improvement).
Sun Pharma Advanced Research Company Limited (SPARC.NS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.